Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic commonly causes nausea, vomiting, diarrhoea, and constipation. However, in non-diabetics using it for weight loss, these symptoms can be more pronounced. The delayed gastric emptying ...

Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss. Who is it for? Wegovy is approved for adults with a body mass index (BMI ...